Resource Type
Guideline
Attachments
Description
Ontario’s Publicly Funded Meningococcal Immunization Program
August, 2026 - Manufacturers have advised that monovalent conjugate meningococcal serogroup C vaccines (Men-C-C) will no longer be available in Canada.
- Ontario will transition to using quadrivalent conjugate meningococcal serogroups A, C, Y, and W vaccines (Men-C-ACYW) for the routine childhood immunization program.
- Communication from the Ontario Ministry of Health is linked above.
- The program change is driven by a discontinuation of Men-C-C vaccines and is not specifically related to changes in provincial meningococcal disease epidemiology but the program change will provide broader protection against additional serogroups (A, Y and W)
- Providers are asked to:
- Continue to administer Men-C-C vaccines (Menjugate Liquid and NeisVac-C) until product expiry.
- Transition to the use of Men-C-ACYW for those 12 months of age, or as required for catch-up, once all Men-C-C inventory is depleted.
- Do not discard usable Men-C-C vaccines prior to expiry.